Abstract
Endometriosis is a chronic inflammatory disease that brings pelvic pain, infertility and a reduced quality of life. Recognising it earlier, and assessing patients with ultrasound early in the work-up, can shorten the diagnostic journey. This thesis summarises the evidence on sonographic diagnosis, fertility-focused management and the investigational role of myo-inositol and D-chiro-inositol. Transvaginal ultrasound remains the first-line imaging test for ovarian and deep disease, although superficial lesions can still escape detection. Inositol derivatives have biologically plausible effects on cell signalling and metabolism, but findings from PCOS research and animal models cannot, by themselves, establish therapeutic efficacy in endometriosis. Controlled studies in women with endometriosis are needed before inositol can be recommended for fertility or any other clinical outcome.
References
1. Becker C. M. et al. ESHRE guideline: endometriosis. Human Reproduction Open, 2022, 2022(2), hoac009.
2. Bonavina G., Taylor H. S. Endometriosis-associated infertility: From pathophysiology to treatment. Frontiers in Endocrinology, 2022, 13, 1020827.
3. Showell M. G. et al. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 2018, 12, CD012378.
4. Placidi M. et al. D-chiro-inositol in a preclinical model of endometriosis. Molecular Medicine, 2025, 31, 134.
5. Kaveh S. et al. Early versus delayed diagnosis of endometriosis and quality of life. Archives of Gynecology and Obstetrics, 2025, 311, 1415–1421.